Fundraising Fox

Syndeio Biosciences

4 known investors

syndeio.bio ↗

Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.

AI & Machine LearningBiotechDigital Health

Investors · 4

Evolution VC PartnersNew York
Tenmile
Catalio Capital ManagementreportedNew York
Palo SantoreportedHighland Park

In the news

Syndeio targets the brain’s connectionscen.acs.org · Nov 2025Syndeio Biosciences launches with molecules to target the synapsecen.acs.org · Jul 2025Syndeio Biosciences emerges with $90m+ funding to combat CNS disordersbioxconomy.com · Jun 2025Karuna, Naurex Alumni Launch New Biotech to Modulate Synaptic Plasticity for Neuro Diseases - BioSpacebiospace.com · May 2025Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics - BioSpacebiospace.com · May 2025Michael McCully — Syndeio Biosciencessyndeio.bio · May 2025

Frequently asked questions

What does Syndeio Biosciences do?
Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.
Who are Syndeio Biosciences's investors?
Syndeio Biosciences's investors include Evolution VC Partners, Tenmile, Catalio Capital Management, Palo Santo.